INNATE PHARMA : INNATE PHARMA ANNOUNCES 1Q2013 REVENUE AND CASH IN LINE WITH EXPECTATIONS

 INNATE PHARMA : INNATE PHARMA ANNOUNCES 1Q2013 REVENUE AND CASH IN LINE WITH
                                 EXPECTATIONS

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the
innate immunity company developing first-in-class drugs for cancer and
inflammatory diseases, announces revenue of 2.7 million euros for the first
quarter of 2013 (3.0 million euros in 1Q2012). The source of this revenue is
Innate Pharma's collaboration and licensing agreement with Bristol-Myers
Squibb, signed in July 2011.
Cash, cash equivalents and current financial instruments of the Company
amounted to 28.4 million euros at March 31, 2013. As at the same date, the
financial liabilities of the Company amounted to 4.4 million euros.


Activity report and Reference Document:
The French version of the 2012 Reference Document, including the Annual
Financial Report,
is available on the Company's website (www.innate-pharma.com). It is also
available on the website of the AMF, the French stock-market authorities
(www.amf-france.org).
The English version of the 2012 Reference Document will be made available on
Innate Pharma's website in May 2012.
The Activity and Responsibility report is already available on Innate Pharma's
website, in French and in English.
Hard copies of these documents are available upon request to the investor
relations department of the Company.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approaches have led to licensing agreements with Novo
Nordisk A/S and Bristol-Myers Squibb.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 83 employees as at March 31,
2013.
Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:
ISIN code: IPH
Ticker code: FR0010331421

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(www.amf-france.org) or on Innate Pharma's website (www.innate-pharma.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:
Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com

ATCG Press
Marielle Bricman
Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com
IPH_Q1_2013

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: INNATE PHARMA via Thomson Reuters ONE
HUG#1699663